Loading
Omeros Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 21 Nov 2023.
Omeros Corp: what insiders have been doing
Omeros Corp, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 18 October 2025 and 18 October 2026, 9 insiders published 38 filings.
The flow runs one way only: 13 sales worth €2.3M, from 4 insiders, and no purchase. Cancelmo Peter B filed the largest sale, €400k, on 1 September 2026, which represents 0.031% of the company's market value.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 38 filings, this issuer sits above that mark. Since 2016, the database holds 2 purchases and 13 sales by insiders of the company.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
50
Thresholds
n/a
Buy Volume
€37,282
2 ops. · all time
Sell Volume
€2M
13 ops. · all time
Who traded when
BuySaleDavid J. Borges6 sales
Arnold C. Hanish3 sales
Cable Thomas J.2 sales
Peter B. Cancelmo2 sales
Analyst consensus: bullish or bearish?
Analysts rate Omeros Corp Buy (bullish), based on 2 analysts. Average price target: US$27.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$18.79
Analyst consensus
2 analystsBuy
US$22.00Target US$27.50(+46%)US$33.00
Income statement
EBITDA-US$121.8M
Net income-US$3.4M324.9% margin
Valuation
PER (trailing)15.4x
PER (forward)15.3x
Beta2.57
Balance sheet & cash
Market capUS$1.4B
Total debtUS$239.1M
Free Cash Flow-US$116.2M
Profitability & ownership
ROA-18.7%
% insiders4.1%
% institutions51.4%
Last declaration on 24 September 2026
Declarations50 total
5,000 shares@ US$3.930.0013% mcap1.5% of flowCommon StockSEC:0001437749-26-031169:0
5,000 shares@ US$2.940.0010% mcap1.1% of flowCommon StockSEC:0001437749-26-031169:1
10,000 shares@ US$20.950.014% mcap15.7% of flowCommon StockSEC:0001437749-26-031169:2
10,000 shares@ US$15.580.011% mcap11.7% of flowCommon StockSEC:0001437749-26-031169:3
10,000 shares@ US$20.950.014% mcap15.8% of flowCommon StockSEC:0001437749-26-031169:4
14,927 shares@ US$21.050.021% mcap41.0% of flowCommonSEC144:0001950047-26-009769
10,000 shares@ US$18.490.013% mcap24.1% of flowCommonSEC144:0001950047-26-009751
25,000 shares@ US$2.940.0049% mcap6.8% of flowCommon StockSEC:0001437749-26-029427:0
25,000 shares@ US$18.64510.031% mcap43.2% of flowCommon StockSEC:0001437749-26-029427:1
25,000 shares@ US$2.940.0050% mcap6.8% of flowCommon StockSEC:0001437749-26-029427:2
25,000 shares@ US$18.54160.031% mcap43.2% of flowCommon StockSEC:0001437749-26-029427:3
25,000 shares@ US$18.54160.031% mcap50.0% of flowCommonSEC144:0001950047-26-008856
25,000 shares@ US$18.64510.031% mcap50.0% of flowCommonSEC144:0001950047-26-008821
5,000 shares@ US$15.810.0053% mcap15.5% of flowCommon StockSEC:0001437749-26-029191:0
5,000 shares@ US$18.52650.0062% mcap18.1% of flowCommon StockSEC:0001437749-26-029191:1
2,500 shares@ US$15.810.0026% mcap7.7% of flowCommon StockSEC:0001437749-26-029191:2
7,500 shares@ US$14.660.0074% mcap21.5% of flowCommon StockSEC:0001437749-26-029191:3
5,000 shares@ US$18.87620.0063% mcap18.5% of flowCommon StockSEC:0001437749-26-029191:4
5,000 shares@ US$19.01610.0064% mcap18.6% of flowCommon StockSEC:0001437749-26-029191:5
10,000 shares@ US$18.94620.013% mcap66.8% of flowCommonSEC144:0001950047-26-008747
5,000 shares@ US$18.82650.0063% mcap33.2% of flowCommonSEC144:0001950047-26-008714
5,906 shares@ US$3.930.0016% mcap1.7% of flowCommon StockSEC:0001437749-26-028951:0
4,094 shares@ US$2.940.0008% mcap0.9% of flowCommon StockSEC:0001437749-26-028951:1
10,000 shares@ US$18.950.013% mcap14.0% of flowCommon StockSEC:0001437749-26-028951:2
906 shares@ US$2.940.0002% mcap0.2% of flowCommon StockSEC:0001437749-26-028951:3
25 of 50 declarations
About Omeros Corp
Omeros Corp. is a U.S.-based biopharmaceutical company listed on the Nasdaq under the ticker OMER. The company is headquartered in Seattle, Washington, United States. Founded in 1994, Omeros has built its business around discovering, developing, and in some cases commercializing first-in-class small-molecule and protein therapeutics. Its profile is that of a specialty biotech with both clinical-stage assets and an emerging commercial footprint, which makes it meaningfully different from a purely pre-revenue development company. ([omeros.com](https://www.omeros.com/about-omeros/?utm_source=openai))
Omeros’ core therapeutic focus spans complement-mediated diseases, immunologic disorders, certain cancers, and addictive or compulsive disorders. Its pipeline includes narsoplimab, an investigational lectin-pathway complement inhibitor, and OMS527, a PDE7 inhibitor being developed for cocaine use disorder. The company also describes a growing portfolio of recombinant antibodies and other oncology-related programs. This diversified scientific approach gives Omeros multiple shots on goal, but it also reflects the high clinical and regulatory risk profile typical of specialty biotech investing. ([investor.omeros.com](https://investor.omeros.com/about-us/default.aspx?utm_source=openai))
Read moreShow less
Commercially, Omeros has begun to generate product revenue. In January 2026, the company launched YARTEMLEA in the U.S. market, and in its first-quarter 2026 update it reported gross product sales of $11.1 million and net sales of $9.9 million. For investors, this is an important milestone because it suggests the company is not relying solely on future pipeline optionality; it is starting to build an operating base around marketed products as well. ([investor.omeros.com](https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Reports-First-Quarter-2026-Financial-Results/default.aspx?utm_source=openai))
From a competitive standpoint, Omeros operates in highly specialized therapeutic niches where scientific differentiation, patent protection, and clinical data are the main sources of advantage. If late-stage data and regulatory outcomes are positive, the company’s orphan and specialty indications could support significant value creation. However, the stock remains exposed to substantial development risk, capital needs, and concentration risk across a limited number of lead assets. Recent financing activity, including a balance-sheet strengthening transaction in 2024 and a $22 million registered direct offering in 2025, underscores the capital-intensive nature of the business. ([investor.omeros.com](https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-further-strengthens-its-balance-sheet-through?utm_source=openai))
For French-speaking investors in France, Belgium, and Switzerland, Omeros should be viewed as a health-care/pharma name with a speculative but potentially asymmetric profile. It combines a U.S. Nasdaq listing, a Seattle headquarters, a research-driven pipeline, and an emerging commercial product base. Recent company disclosures and SEC Form 4 insider-filing activity suggest ongoing capital management and insider-trading monitoring remain relevant parts of the investment case. ([investor.omeros.com](https://investor.omeros.com/static-files/d2b387a5-961a-4757-bf4c-bcca55b1ab45?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
